XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
11 EARNINGS (LOSS) PER SHARE
9 Months Ended 12 Months Ended
Sep. 30, 2017
Dec. 31, 2016
Accounting Policies [Abstract]    
EARNINGS (LOSS) PER SHARE

A reconciliation of net income and weighted average shares used in computing basic and diluted net income per share is as follows:

 

  Nine Months ended September 30,2017 Nine Months ended September 30,2016
Net income (loss) attributable to common stock holders   $ (9,615,628)   $ (4,082,006)
Weighted average common shares outstanding     14,472,322     12,794,149
Basic net income (loss) per share of common stock   $ (0.66)   $ (0.32)
Diluted net income (loss) per share of common stock   $ (0.66)   $ (0.32)

 

Share based awards, inclusive of all grants made under the Plan, for which either the stock option exercise price or the fair value of the restricted share award exceeds the average market price over the period, have an anti- dilutive effect on earnings per share, and accordingly, are excluded from the diluted computations for all periods presented.

 

A reconciliation of net income and weighted average shares used in computing basic and diluted net income per share is as follows:

 

    Twelve Months Ended
    December 31,
    2016   2015
         
Basic net income (loss) per share:                
Net income (loss) applicable to common shares   $ (2,788,112 )   $ (814,075 )
Weighted average common shares outstanding     13,068,597       11,101,198  
Basic net income (loss) per share of common stock   $ (0.21 )   $ (0.07 )
Diluted net income (loss) per share:                
Net income (loss) applicable to common shares   $ (2,788,112 )   $ (814,075 )
Weighted average common shares outstanding     13,068,597       11,101,198  
Dilutive effects of convertible debt, stock options and warrants     -       -  
Weighted average common shares, assuming dilutive effect of stock options     13,068,597       11,101,198  
Diluted net income (loss) per share of common stock   $ (0.21 )   $ (0.07 )

 

Share-based awards, inclusive of all grants made under the Company’s equity plans, for which either the stock option exercise price or the fair value of the restricted share award exceeds the average market price over the period, have an anti-dilutive effect on earnings per share, and accordingly, are excluded from the diluted computations for all periods presented.

 

During the twelve months ended December 31, 2016, we granted our directors and employees options to purchase 782,700 shares of our common stock and restricted stock units for 507,680 shares of our common stock. As of December 31, 2016, we had outstanding options to purchase 972,700 shares of the Company's common stock and restricted stock units for 590,869 shares of the Company’s common stock, resulting in share-based awards for a total of 1,563,569 shares of our common stock outstanding under the Plan leaving 436,431 share-based units available under the Plan.

 

Due to the Company’s net loss, potential dilutive shares were not included in the calculation of diluted EPS on December 31, 2016, as it will have an antidilutive effect.